J Korean Ophthalmol Soc > Volume 58(9); 2017 > Article
Journal of the Korean Ophthalmological Society 2017;58(9):1080-1086.
DOI: https://doi.org/10.3341/jkos.2017.58.9.1080    Published online September 15, 2017.
Efficacy of Primary Intravitreal Ranibizumab Injection for Treatment of Type 1 Retinopathy of Prematurity.
Gyu Chul Chung, Sung Hyuk Moon
1Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. koils79@naver.com
2T2B Infrastructure Center for Ocular Disease, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
1형 미숙아망막병증의 치료로서 일차 유리체강내 라니비주맙 주입술의 효과
정규철1,2⋅문성혁1,2
인제대학교 의과대학 부산백병원 안과학교실1, 인제대학교 의과대학 부산백병원 안과질환 T2B 기반구축센터2
Correspondence:  Sung-Hyuk Moon
Email: koils79@naver.com
Received: 29 June 2017   • Revised: 1 August 2017   • Accepted: 23 August 2017
Abstract
PURPOSE
To evaluate the effectiveness and safety of primary intravitreal ranibizumab injection as a treatment for retinopathy of prematurity. METHODS: Retrospective analysis of the medical records of patients diagnosed with retinopathy of prematurity and treated with intravitreal ranibizumab injection from January 1, 2013 to January 1, 2016 was performed. We complied with the standards for ‘prethresold, type 1’ established by the Early Treatment of Retinopathy of Prematurity study for intravitreal ranibizumab injection. The follow-up period after injection was at least 9 months. Patients who received additional treatment such as laser photocoagulation or intravitreal injection without reactivation of retinopathy of prematurity were excluded. RESULTS: A total of 21 patients (39 eyes) were included in this study. Nine (16 eyes) were male and 12 (23 eyes) were female. The average duration between treatment decision and intravitreal ranibizumab injection was 2.1 ± 1.5 days. Complete regression of the plus sign occurred 18.2 ± 9.1days after injection. One eye with reactivation was treated with panretinal laser photocoagulation while four other eyes with reactivation were treated with intravitreal bevacizumab injection. There were 87.1% (34/39) eyes that underwent primary intravitreal ranibizumab injection with stable results without any reactivation. There were no systemic complications related to intravitreal ranibizumab injection. CONCLUSIONS: Primary intravitreal ranibizumab injection as a treatment for retinopathy of prematurity showed good efficacy and safety. However, thorough evaluation is needed after primary intravitreal ranibizumab injection due to the potential for reactivation. Long-term monitoring is needed after intravitreal ranibizumab injection.
Key Words: Intravitreal injection;Ranibizumab;Retinopathy of prematurity;Type 1


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next